Jari Tevajarvi News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jari tevajarvi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jari Tevajarvi Today - Breaking & Trending Today

India's largest vial maker expects sales to triple on vaccine ramp up

Read more about India s largest vial maker expects sales to triple on vaccine ramp up on Business Standard. Schott Kaisha is also in talks with Indian manufacturers of Russia s Sputnik V vaccine to supply millions of vials, but is yet to receive bulk orders ....

Astrazeneca Covid , Rishad Dadachanji , Jari Tevajarvi , Schott Kaisha , Serum Institute , Serum Institute Of India , Director Rishad Dadachanji , Corona Virus , Coronavirus Vaccine , Vaccine Doses , Ial Makers , சீரம் நிறுவனம் , சீரம் நிறுவனம் ஆஃப் இந்தியா , கொரோனா வைரஸ் ,

India's largest vial maker expects sales to triple on COVID-19 vaccine ramp up


 20 May 2021 - 9:41
Picture used for representation
Reuters
Bengaluru: Indian drug vial maker Schott Kaisha is expecting annual vial sales for COVID-19 shots to more than triple as vaccine production, including by one of its top customers Serum Institute, increases in response to a monster second wave of infections.
An Indo-German joint venture between specialty glass makers Schott AG and Kaisha, the company expects to sell 380 million vials for COVID-19 vaccines in 2021-22, up from 113 million a year earlier, Director Rishad Dadachanji said in an interview.
The demand from our major customers has gone up two-fold, and is indicated to go up three-fold in the near future, Dadachanji said. ....

Rishad Dadachanji , Jari Tevajarvi , Schott Kaisha , Serum Institute , Serum Institute Of India , Director Rishad Dadachanji , சீரம் நிறுவனம் , சீரம் நிறுவனம் ஆஃப் இந்தியா ,

India's largest vial maker expects sales to triple on COVID-19 vaccine ramp-up


India s largest vial maker expects sales to triple on COVID-19 vaccine ramp-up
May 20, 2021 10:10 PM PHT
Reuters
Indian drug vial maker Schott Kaisha is expecting annual vial sales for COVID-19 shots to more than triple as vaccine production, including by one of its top customers Serum Institute, increases in response to a monster second wave of infections.
An Indo-German joint venture between specialty glass makers Schott AG and Kaisha, the company expects to sell 380 million vials for COVID-19 vaccines in 2021-2022, up from 113 million a year earlier, director Rishad Dadachanji said in an interview.
The demand from our major customers has gone up twofold, and is indicated to go up threefold in the near future, Dadachanji said. ....

Jari Tevajarvi , Medical Supplies , Covid 19 , மருத்துவ பொருட்கள் ,